These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 34272171)

  • 61. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
    Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Thrombocytopenia in patients with myelofibrosis: management options in the era of JAK inhibitor therapy.
    Benevolo G; Elli EM; Guglielmelli P; Ricco A; Maffioli M
    Leuk Lymphoma; 2020 Jul; 61(7):1535-1547. PubMed ID: 32093511
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
    Lancman G; Mascarenhas J
    Expert Rev Hematol; 2017 Jan; 10(1):23-28. PubMed ID: 27882812
    [TBL] [Abstract][Full Text] [Related]  

  • 64. New Treatments for Myelofibrosis.
    Tremblay D; Mesa R
    Curr Treat Options Oncol; 2023 Feb; 24(2):61-75. PubMed ID: 36640223
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacotherapy of Myelofibrosis.
    Tremblay D; Marcellino B; Mascarenhas J
    Drugs; 2017 Sep; 77(14):1549-1563. PubMed ID: 28791654
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical Utility of Fedratinib in Myelofibrosis.
    Waksal JA; Tremblay D; Mascarenhas J
    Onco Targets Ther; 2021; 14():4509-4521. PubMed ID: 34456572
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Momelotinib in myelofibrosis.
    Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Fragliasso V; Neri A; Morabito F; Vigna E; Gentile M
    Expert Opin Pharmacother; 2024 Apr; 25(5):521-528. PubMed ID: 38623844
    [TBL] [Abstract][Full Text] [Related]  

  • 68. How many JAK inhibitors in myelofibrosis?
    Ferreira BV; Harrison C
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
    Verstovsek S; Mesa RA; Livingston RA; Hu W; Mascarenhas J
    J Hematol Oncol; 2023 Jul; 16(1):82. PubMed ID: 37501130
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia.
    Mascarenhas J
    Expert Rev Hematol; 2022 Aug; 15(8):671-684. PubMed ID: 35983661
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Emerging Treatment Options for Myelofibrosis: Focus on Anemia.
    Sastow D; Tremblay D
    Ther Clin Risk Manag; 2023; 19():535-547. PubMed ID: 37404252
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors.
    Duminuco A; Vetro C; Giallongo C; Palumbo GA
    Expert Opin Pharmacother; 2023; 24(13):1449-1461. PubMed ID: 37341682
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Optimizing the management of patients with myelofibrosis.
    Manea PJ
    Clin J Oncol Nurs; 2014 Jun; 18(3):330-7. PubMed ID: 24867113
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2023 May; 98(5):801-821. PubMed ID: 36680511
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
    Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
    Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
    [TBL] [Abstract][Full Text] [Related]  

  • 76. ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis.
    Duminuco A; Chifotides HT; Giallongo S; Giallongo C; Tibullo D; Palumbo GA
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201581
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clarifying the use of ruxolitinib in patients with myelofibrosis.
    Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
    Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The use of JAK inhibitors for low-risk myelofibrosis.
    Alimam S; McLornan D; Harrison C
    Expert Rev Hematol; 2015 Oct; 8(5):551-3. PubMed ID: 26343888
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.
    Diaz AE; Mesa RA
    Future Oncol; 2018 Apr; 14(9):797-807. PubMed ID: 29235894
    [TBL] [Abstract][Full Text] [Related]  

  • 80. JAK inhibitors in the treatment of myelofibrosis.
    Levavi H; Hoffman R; Marcellino BK
    Clin Adv Hematol Oncol; 2022 Jul; 20(7):456-467. PubMed ID: 35802878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.